Search review questions

Secondary outcome: cost of intervention · ulceration and other skin changes caused by nerve damage in leprosy

Primary outcome: prevention of ulcer · ulceration and other skin changes caused by nerve damage in leprosy

Primary outcome: healing of ulcer (mean change of wound size (mm3) after 8 months treatment) · ulceration and other skin changes caused by nerve damage in leprosy

Primary outcome: adverse events · ulceration and other skin changes caused by nerve damage in leprosy

Secondary outcome: costs · ulceration caused by nerve damage in leprosy

Secondary outcome: quality of life · ulceration and other skin changes caused by nerve damage in leprosy

Secondary outcome: acceptability of treatment · ulceration and other skin changes caused by nerve damage in leprosy

Secondary outcome: cost of intervention · ulceration and other skin changes caused by nerve damage in leprosy

Primary outcome: healing of ulcer · skin changes caused by nerve damage in leprosy

Tertiary outcome: prevention and treatment of other skin changes (number of feet being fissure‐ and callous‐free at 6 weeks) · skin changes caused by nerve damage in leprosy

Primary outcome: prevention of ulcer · skin changes caused by nerve damage in leprosy

Primary outcome: adverse effects · skin changes caused by nerve damage in leprosy

Secondary outcome: quality of life · skin changes caused by nerve damage in leprosy

Secondary outcome: acceptability of treatment (at 6 weeks) · skin changes caused by nerve damage in leprosy

Secondary outome: cost of intervention · skin changes caused by nerve damage in leprosy

Primary outcome: prevention of ulcers · ulceration and other skin changes caused by nerve damage in leprosy

Primary outcome: prevention of ulcer · ulceration caused by nerve damage in leprosy

Primary outcome: healing of ulcer (size, cm², at 8 weeks) · ulceration caused by nerve damage in leprosy

Primary outcome: healing of ulcer (depth, cm², at 8 weeks) · ulceration caused by nerve damage in leprosy

Primary outcome: adverse events · ulceration caused by nerve damage in leprosy

Secondary outcome: quality of life · ulceration caused by nerve damage in leprosy

Secondary outcome: acceptability of treatment · ulceration caused by nerve damage in leprosy

Secondary outome: cost of intervention · ulceration caused by nerve damage in leprosy

Primary outcome: prevention of ulcer · ulceration caused by nerve damage in leprosy

Primary outcome: healing of ulcer (size, cm2 at 8 weeks) · ulceration caused by nerve damage in leprosy

Primary outcome: healing of ulcer (depth, cm2 at 8 weeks) · ulceration caused by nerve damage in leprosy

Primary outcome: healing of ulcers (mean reduction of ulcer area at 6 weeks (mm2)) · ulceration and other skin changes caused by nerve damage in leprosy

Primary outcome: adverse events · ulceration caused by nerve damage in leprosy

Secondary outcome: quality of life · ulceration caused by nerve damage in leprosy

Secondary outcome: acceptability of treatment · ulceration caused by nerve damage in leprosy

Secondary outome: cost of intervention · ulceration caused by nerve damage in leprosy

Primary outcome: prevention of ulcer · ulceration caused by nerve damage in leprosy

Primary outcome: healing of ulcer (size, cm2, at 8 weeks) · ulceration caused by nerve damage in leprosy

Primary outcome: healing of ulcer (depth, cm2, at 8 weeks) · ulceration caused by nerve damage in leprosy

Primary outcome: adverse events · ulceration caused by nerve damage in leprosy

Secondary outcome: quality of life · ulceration caused by nerve damage in leprosy

Secondary outcome: acceptability of treatment · ulceration caused by nerve damage in leprosy

The proportion of participants developing any signs and symptoms of OIHD (incident cases) measured by clinical scores (IGA) or hand dermatitis scores (e.g. HECSI, Manuscore), or both, as rated by the investigator (physician/nurse) or the participa... · workers at risk of occupational irritant hand dermatitis

Frequency of treatment discontinuation due to adverse effects · workers at risk of occupational irritant hand dermatitis

The proportion of participants developing any signs and symptoms of OIHD (incident cases) measured by clinical scores (IGA) or hand dermatitis scores (e.g. HECSI, Manuscore), or both, as rated by the investigator (physician/nurse) or the participa... · workers at risk of occupational irritant hand dermatitis

Frequency of treatment discontinuation due to adverse effects · workers at risk of occupational irritant hand dermatitis

The proportion of participants developing any signs and symptoms of OIHD (incident cases) measured by clinical scores (IGA) or hand dermatitis scores (e.g. HECSI, Manuscore), or both, as rated by the investigator (physician/nurse) or the participa... · workers at risk of occupational irritant hand dermatitis

Frequency of treatment discontinuation due to adverse effects · workers at risk of occupational irritant hand dermatitis

The proportion of participants developing any signs and symptoms of OIHD (incident cases) measured by clinical scores (IGA) or hand dermatitis scores (e.g. HECSI, Manuscore), or both, as rated by the investigator (physician/nurse) or the participa... · workers at risk of occupational irritant hand dermatitis

Frequency of treatment discontinuation due to adverse effects · workers at risk of occupational irritant hand dermatitis

Primary outcome 1: participant‐ or parent‐rated symptoms of eczema (SCORAD part C) at the end of active treatment Visual analogue scale for itch and sleep disturbance ranging from 0 to 10 for each symptom and combined ranging from 0 to 20. The hig... · male and female patients 0 to 55 years of age with physician‐diagnosed eczema

Primary outcome 1: participant‐ or parent‐rated global change in eczema symptoms at the end of active treatment (binary outcome) Change in risk for worsened/unchanged eczema Duration of · male and female patients 0 to 55 years of age with physician‐diagnosed eczema

Primary outcome 2: participant‐ or parent‐rated participant quality of life score at the end of active treatment Scales used: DLQI, IDQoL, Skindex‐29, CDLQI. On those scales, the higher the score, the more severely the quality of life is affected ... · male and female patients 0 to 55 years of age with physician‐diagnosed eczema

Primary outcome 2: participant‐ or parent‐rated family quality of life score at the end of active treatment Scale used: DFI, FDLQI. On those scales, the higher the score, the more severely the quality of life is affected Duration of · male and female patients 0 to 55 years of age with physician‐diagnosed eczema

Secondary outcome 4: global eczema severity score (total SCORAD) at the end of active treatment (Investigator‐rated eczema severity) Scale used: total SCORAD ranging from 0 to 103. The higher the score, the more severe the disease Duration of · male and female patients 0 to 55 years of age with physician‐diagnosed eczema